Miki A - Search Results

1

A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population.

Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. Yanagisawa S, et al. Among authors: miki a. PLoS One. 2011;6(12):e28847. doi: 10.1371/journal.pone.0028847. Epub 2011 Dec 12. PLoS One. 2011. PMID: 22174912 Free PMC article.

2

Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2).

Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. Yanagisawa S, et al. Among authors: miki a. Mol Vis. 2011;17:3574-82. Epub 2011 Dec 31. Mol Vis. 2011. PMID: 22219653 Free PMC article.

3

The association of age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) variants with two angiographic subtypes of polypoidal choroidal vasculopathy.

Miki A, Honda S, Kondo N, Negi A. Miki A, et al. Ophthalmic Genet. 2013 Sep;34(3):146-50. doi: 10.3109/13816810.2012.749288. Epub 2013 Jan 4. Ophthalmic Genet. 2013. PMID: 23289808

4

Loss of aquaporin 9 expression adversely affects the survival of retinal ganglion cells.

Miki A, Kanamori A, Negi A, Naka M, Nakamura M. Miki A, et al. Am J Pathol. 2013 May;182(5):1727-39. doi: 10.1016/j.ajpath.2013.01.027. Epub 2013 Mar 16. Am J Pathol. 2013. PMID: 23506846

5

Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.

Miki A, Honda S, Kojima H, Nishizaki M, Nagai T, Fujihara M, Uenishi M, Kita M, Kurimoto Y, Negi A; Hyogo Macular Disease Study Group. Miki A, et al. Jpn J Ophthalmol. 2013 May;57(3):301-7. doi: 10.1007/s10384-013-0237-9. Epub 2013 Mar 19. Jpn J Ophthalmol. 2013. PMID: 23508554

6

Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study.

Miki A, Honda S, Nagai T, Tsukahara Y, Negi A. Miki A, et al. Br J Ophthalmol. 2013 Jun;97(6):770-4. doi: 10.1136/bjophthalmol-2012-303007. Epub 2013 Apr 19. Br J Ophthalmol. 2013. PMID: 23603482 Clinical Trial.

7

Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy.

Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Miki A, et al. Ophthalmology. 2014 May;121(5):1067-72. doi: 10.1016/j.ophtha.2013.11.020. Epub 2013 Dec 21. Ophthalmology. 2014. PMID: 24365176

8

Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration.

Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Matsumiya W, et al. Among authors: miki a. Pharmacogenomics. 2014 Apr;15(6):833-43. doi: 10.2217/pgs.14.51. Pharmacogenomics. 2014. PMID: 24897289

9

Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy.

Honda S, Miki A, Yanagisawa S, Matsumiya W, Nagai T, Tsukahara Y. Honda S, et al. Among authors: miki a. Ophthalmologica. 2014;232(2):92-6. doi: 10.1159/000360308. Epub 2014 Jun 27. Ophthalmologica. 2014. PMID: 24993059

10

The expression of syntaphilin is down-regulated in the optic nerve after axonal injury.

Miki A, Kanamori A, Nakamura M, Matsumoto Y, Mizokami J, Negi A. Miki A, et al. Exp Eye Res. 2014 Dec;129:38-47. doi: 10.1016/j.exer.2014.10.017. Epub 2014 Oct 24. Exp Eye Res. 2014. PMID: 25447562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

681 results

Search Page

Filters